Furthermore, the anti-ROR1 blocking antibody cirmtuzumab has shown efficacy in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) trials [247]. The gene discussed is ROR1; the disease is mantle cell lymphoma.